ライフサイエンスコーパス: Lindau disease

1 molecular interventions in ocular von Hippel-Lindau disease.

2 tants may rescue pVHL function in von Hippel-Lindau disease.

3 erization and treatment of ocular von Hippel-Lindau disease.

4 hich can occur sporadically or in von Hippel-Lindau disease.

5 pathogenesis of renal cancer and von Hippel-Lindau disease.

6 gement, and treatment options for von Hippel-Lindau disease.

7 isposition to pheochromocytoma in von Hippel-Lindau disease.

8 should be screened for MEN-2 and Von Hippel-Lindau disease.

9 al cancer predisposition syndrome von Hippel-Lindau disease.

10 with or without association with von Hippel-Lindau disease.

11 tion in the VHL gene leads to the von Hippel-Lindau disease, a familial syndrome characterized by ben

12 protein (pVHL) is associated with von Hippel-Lindau disease, an inherited cancer syndrome, as well as

13 We studied 26 patients with von Hippel-Lindau disease and 9 patients with MEN-2 who had histolo

14 renal cancers in adults included von Hippel-Lindau disease and a rare form of chromosomal translocat

15 umors (ELSTs) are associated with von Hippel-Lindau disease and cause irreversible sensorineural hear

16 erial evaluation of patients with von Hippel-Lindau disease and ELSTs at the National Institutes of H

17 Thirty-five patients with von Hippel-Lindau disease and ELSTs in 38 ears (3 bilateral ELSTs)

18 e is inactivated in patients with von Hippel-Lindau disease and in most sporadic clear cell renal car

19 Von Hippel-Lindau disease and MEN-2 were diagnosed on the basis of

20 important in the pathogenesis of von Hippel-Lindau disease and RCC.

21 of the molecular pathogenesis of von Hippel-Lindau disease and the role of the VHL gene product (pVH

22 prior clinical manifestations of von Hippel-Lindau disease and, as expected, had germline von Hippel

23 tiple endocrine neoplasia type 2, von Hippel-Lindau disease, and familial adenomatous polyposis are e

24 e predisposes patients to develop von Hippel-Lindau disease, and somatic VHL inactivation is an early

25 Patients affected with von Hippel-Lindau disease are at risk of developing multiple indepe

26 se may inform us as to how ocular von Hippel-Lindau disease arises, and help guide molecular interven

27 mutations have been found in both von Hippel-Lindau disease-associated and sporadic RCCs.

28 ) mRNA is upregulated in RCC- and von Hippel-Lindau disease-associated tumors.

29 f renal cancer syndromes includes von Hippel-Lindau disease, Birt-Hogg-Dube syndrome, hereditary papi

30 The von Hippel-Lindau disease gene (VHL) is the causative gene for most

31 One patient with von Hippel-Lindau disease had a normal plasma normetanephrine conce

32 phrine, whereas the patients with von Hippel-Lindau disease had almost exclusively high plasma concen

33 inical characterization of ocular von Hippel-Lindau disease has been limited by small patient numbers

34 von Hippel-Lindau disease is a hereditary cancer syndrome.

35 von Hippel-Lindau disease is a heritable multisystem cancer syndrom

36 von Hippel-Lindau disease is an inherited, multisystemic cancer syn

37 characterization of the impact of von Hippel-Lindau disease on eye health and visual function.

38 Twenty-one patients with von Hippel-Lindau disease or hereditary papillary renal cancer unde

39 hromocytomas and 50 patients with von Hippel-Lindau disease or MEN-2 who had no radiologic evidence o

40 heochromocytomas in patients with von Hippel-Lindau disease or MEN-2.

41 ese tumors, such as patients with von Hippel-Lindau disease or multiple endocrine neoplasia type 2 (M

42 2, von Recklinghausen's disease, von Hippel-Lindau disease, or Carney's syndrome.

43 on postmortem tissues from three von Hippel-Lindau disease patients (not in the clinical series).

44 with the clinical findings in 16 von Hippel-Lindau disease patients with 22 CNS hemangioblastomas (1

45 ance imaging (MRI) is obtained in von Hippel-Lindau disease patients, hemangioblastomas provide an op

46 creening studies in patients with von Hippel-Lindau disease should be interpreted cautiously because

47 argeting the molecular biology of von Hippel-Lindau disease, some of which are presently being invest

48 von Hippel-Lindau disease (VHL [MIM 193300]) is a heritable autosom

49 ses of inherited renal carcinoma, von Hippel-Lindau disease (VHL) and the chromosome translocation (3

50 Patients with von Hippel-Lindau disease (VHL) are at risk to develop multiple tum

51 von Hippel-Lindau disease (VHL) is a dominantly inherited familial

52 von Hippel-Lindau disease (VHL) is an autosomal-dominant neoplasia

53 ne tumors (PNETs) associated with von Hippel-Lindau disease (VHL) is challenging because of the malig

54 Von Hippel-Lindau disease (VHL) is one of the most common inherited

55 von Hippel-Lindau disease (VHL) patients develop highly vascular tu

56 tiple endocrine neoplasia type 2, von Hippel-Lindau disease (VHL), and, very rarely, type 1 neurofibr

57 eochromocytoma susceptibility are von Hippel-Lindau disease (VHL), multiple endocrine neoplasia type

58 he promoter methylation status of von Hippel-Lindau disease (VHL), retinoic acid receptor beta (RAR-b

59 e in the general population, with von Hippel-Lindau disease (VHL).

60 linically and genetically defined von Hippel-Lindau disease was systemically characterized in a singl